Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00767507 · ClinicalTrials.gov registry record · Phase 2
Maintenance of Platelet Inhibition With Cangrelor
A Phase 2 study of Acute Coronary Syndrome (ACS), sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
- 1
- Study location
NCT00767507 is a Phase 2 study of Acute Coronary Syndrome (ACS) that has completed, run by The Medicines Company. The registered enrollment target is 221 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00767507, a Phase 2 study of Acute Coronary Syndrome (ACS), has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG cangrelor
Study Locations (1)
California
- Scripps Clinic / Scripps Green Hospital - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00767507
The ClinicalTrials.gov registry entry for NCT00767507 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Coronary Syndrome (ACS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00767507 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00767507 about?
NCT00767507 is a clinical study titled "Maintenance of Platelet Inhibition With Cangrelor". The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
What is the current status of trial NCT00767507?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2008-10. Estimated completion is 2011-07.
What conditions does trial NCT00767507 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome (ACS).
What interventions are being tested in trial NCT00767507?
The interventions under investigation include: Placebo (OTHER), cangrelor (DRUG).
Who is sponsoring clinical trial NCT00767507?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00767507 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome (ACS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.